Last reviewed · How we verify
placebo, aspirine, clopidogrel
This is a combination study comparing placebo, aspirin (a non-selective cyclooxygenase inhibitor), and clopidogrel (a P2Y12 platelet receptor antagonist) for antiplatelet effects.
This is a combination study comparing placebo, aspirin (a non-selective cyclooxygenase inhibitor), and clopidogrel (a P2Y12 platelet receptor antagonist) for antiplatelet effects. Used for Acute coronary syndrome, Stroke prevention, Peripheral arterial disease.
At a glance
| Generic name | placebo, aspirine, clopidogrel |
|---|---|
| Sponsor | University Hospital, Angers |
| Drug class | Antiplatelet agents |
| Target | Cyclooxygenase (aspirin); P2Y12 receptor (clopidogrel) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase enzymes, reducing thromboxane A2 production and platelet aggregation. Clopidogrel is a thienopyridine that irreversibly blocks the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet activation and aggregation. Placebo serves as the control arm. These agents work through distinct mechanisms to inhibit platelet function and reduce thrombotic events.
Approved indications
- Acute coronary syndrome
- Stroke prevention
- Peripheral arterial disease
Common side effects
- Bleeding
- Gastrointestinal upset (aspirin)
- Dyspepsia
- Rash (clopidogrel)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo, aspirine, clopidogrel CI brief — competitive landscape report
- placebo, aspirine, clopidogrel updates RSS · CI watch RSS
- University Hospital, Angers portfolio CI